GSK962040: A small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility

Neurogastroenterology and Motility

Volumn 21, Issue 6, 2009, Pages

  Sanger, G J ^a   Westaway, S M ^a   Barnes, A A ^a   MacPherson, D T ^a   Muir, A I ^a   Jarvie, E M ^a   Bolton, V N ^a   Cellek, S ^a   Naslund E ^b   Hellstrom P M ^c   Borman, R A ^a   Unsworth, W P ^a   Matthews, K L ^a   Lee, K ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b DANDERYD HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

GSK962040; Human; Motilin; Rabbit; Stomach

Indexed keywords

CENTRAL STIMULANT AGENT; ERYTHROMYCIN; GHRELIN; GSK 962040; ION CHANNEL; MOTILIN; N (3 FLUOROPHENYL) 1 [(4 {[(3S) 3 METHYL 1 PIPERAZINYL]METHYL}PHENYL)ACETYL] 4 PIPERIDINAMINE; UNCLASSIFIED DRUG;

AMPLITUDE MODULATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONSCIOUSNESS; CONTROLLED STUDY; DEFECATION; FECES; GASTROINTESTINAL MOTILITY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MUSCLE CONTRACTION; NONHUMAN; PRIORITY JOURNAL; RABBIT; STOMACH ANTRUM;

ANIMALS; DEFECATION; ELECTRIC STIMULATION; ERYTHROMYCIN; GALLBLADDER EMPTYING; GASTROINTESTINAL MOTILITY; HUMANS; MALE; MOTILIN; PARASYMPATHETIC NERVOUS SYSTEM; PIPERAZINES; PIPERIDINES; PYLORIC ANTRUM; RABBITS; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, NEUROPEPTIDE; RECOMBINANT PROTEINS; STIMULATION, CHEMICAL; SUBSTRATE SPECIFICITY;

EID: 65949105077     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2009.01270.x     Document Type: Article

References (43)

1. Dibaise JK, Quigley EM. Efficacy of prolonged administration of intravenous erythromycin in an ambulatory setting as treatment of severe gastroparesis: one centre's experience. J Clin Gastroenterol 1999 28 : 131 4. (Pubitemid 29106563)
2. Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003 98 : 259 63. (Pubitemid 36232369)
3. Gonlachanvit S, Hsu CW, Boden GH et al. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. Dig Dis Sci 2003 48 : 488 97. (Pubitemid 36324155)
4. Ritz MA, Chapman MJ, Fraser RJ et al. Erythromycin dose of 70 mg accelerates gastric emptying as effectively as 200 mg in the critically ill. Intensive Care Med 2005 31 : 949 54. (Pubitemid 40941727)
5. Levy H, Hayes J, Boivin M, Tomba T. Transpyloric feeding tube placement in critically ill patients using electromyogram and erythromycin infusion. Chest 2004 125 : 587 91. (Pubitemid 38223640)
6. Carbonell N, Pauwels A, Serfaty L, Boelle PY, Becquemont L, Poupon R. Erythromycin infusion prior to endoscopy for acute upper gastrointestinal bleeding: a randomised, controlled, double-blind trial. Am J Gastroenterol 2006 101 : 1211 5. (Pubitemid 43829984)
7. Abrahamsson H. Treatment options for patients with severe gastroparesis. Gut 2007 56 : 877 83. (Pubitemid 46854207)
8. Hawkyard CV, Koerner RJ. The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks. J Antimicrobial Chemother 2007 59 : 347 58. (Pubitemid 47073441)
9. Linnik MD, Butler BT, Gaddis RR, Ahmed NK. Analysis of serotonergic mechanisms underlying benzamide-induced gastroprokinesis. J Pharmacol Exp Ther 1991 259 : 501 7.
10. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement - a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006 3 : 128 48.
11. Sanger GJ, Alpers D. Development of drugs for gastrointestinal motor disorders: translating science to clinical need. Neurogastroenterol Motil 2008 20 : 177 84.
12. McCallum RW, Cynshi O, US Investigative Team. Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial. Aliment Pharmacol Ther 2007 26 : 107 16. (Pubitemid 46889836)
13. Talley NJ, Verlinden M, Geenen DJ et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 2001 49 : 395 401. (Pubitemid 32802575)
14. Talley NJ, Verlinden M, Snape W et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000 14 : 1653 61. (Pubitemid 32011739)
15. Tack J, Peeters T. What comes after macrolides and other motilin stimulants? Gut 2001 49 : 317 8. (Pubitemid 32802560)
16. Camilleri M. Motilin agonists and dyspepsia: throwing out the baby with the bath water. Gut 2002 51 : 612.
17. Nieuwenhuijs VB, van Duijvenbode-Beumer H, Verheem A et al. The effects of ABT-229 and octreotide on interdigestive small bowel motility, bacterial overgrowth and bacterial translocation in rats. Eur J Clin Invest 1999 29 : 33 40. (Pubitemid 29084246)
18. Sanger GJ. Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases. Drug Discov Today 2008 13 : 234 9.
19. Wisialowski T, Crimin K, Engtrakul J, O'Donnell J, Fermini B, Fossa AA. Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. J Pharmacol Exp Ther 2006 318 : 352 9. (Pubitemid 43920776)
20. Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S, Ohashi K. Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol 2007 47 : 871 6.
21. Li JJ, Chao H-G, Wang H et al. Discovery of a potent and novel motilin agonist. J Med Chem 2004 47 : 1704 8. (Pubitemid 38380913)
22. Heightman TD, Conway E, Corbett DF et al. Identification of novel small molecule agonists of the motilin receptor. Bioorg Med Chem Lett 2008 18 : 6423 8.
23. Westaway SM, Brown SL, Conway E et al. The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor. Bioorg Med Chem Lett 2008 18 : 6429 36.
24. Witherington J, Abberley L, Briggs MA et al. Potent achiral agonists of the growth hormone secretatgogue (ghrelin) receptor. Part 2 - Lead optimisation. Bioorg Med Chem Lett 2008 18 : 2203 5.
25. Jarvie EM, North Laidler VJ, Corcoran S, Bassil A, Sanger GJ. Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro. Br J Pharmacol 2007 150 : 455 62. (Pubitemid 46280656)
26. Dass NB, Hill J, Muir A, Testa T, Wise A, Sanger GJ. The rabbit motilin receptor: molecular characterisation and pharmacology. Br J Pharmacol 2003 140 : 948 54. (Pubitemid 37464078)
27. Coulie B, Tack J, Peeters T, Janssens J. Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut 1998 43 : 395 400. (Pubitemid 28414922)
28. Matsuura B, Dong M, Naik S, Miller LJ, Onji M. Differential contributions of motilin receptor extracellular domains for peptide and non-peptidyl agonist binding and activity. J Biol Chem 2006 281 : 12390 6. (Pubitemid 43855323)
29. Blondeau JM, DeCarolis E, Metzler KL, Hansen GT. The macrolides. Expert Opin Investig Drugs 2002 11 : 189 215. (Pubitemid 34144867)
30. Thielemans L, Depoortere I, Perret J et al. Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther 2005 313 : 1397 405. (Pubitemid 40727047)
31. 13]-motilin in the isolated rabbit gastric antrum. Eur J Pharmacol 1997 337 : 267 74. (Pubitemid 27507793)
32. Depoortere I, Thijs T, Thielemans L, Robberecht P, Peeters TL. Interaction of the growth hormone-releasing peptides ghrelin and growth hormone-releasing peptide-6 with the motilin receptor in the rabbit gastric antrum. J Pharmacol Exp Ther 2003 305 : 660 7. (Pubitemid 36459184)
33. 13]motilin in E.coli. Biotechnol Lett 1988 10 : 763 8. (Pubitemid 19000742)
34. 13-motilin (KW-5139)-evoked release of acetylcholine from enteric neurones in the rabbit duodenum. Br J Pharmacol 1993 109 : 94 9. (Pubitemid 23113805)
35. Costa A, De Ponti F, Gibelli G, Crema F, d'Angelo L. In vivo characterisation of the colonic prokinetic effect of erythromycin in the rabbit. Pharmacology 1997 54 : 64 75. (Pubitemid 27117224)
36. Depoortere I, Peeters TL, Vantrappen G. Motilin receptors of the rabbit colon. Peptides 1991 12 : 89 94.
37. Sudo H, Ozaki K, Muramatsu H et al. Mitemcinal (GM-611), an orally active motilin agonist, facilitates defecation in rabbits and dogs without causing loose stools. Neurogastroenterol Motil 2007 19 : 318 26. (Pubitemid 46474786)
38. Jameson JS, Rogers J, Misiewicz JJ, Raimundo AH, Henry MM. Oral or intravenous erythromycin has no effect on human distal colonic motility. Aliment Pharmacol Ther 1992 6 : 589 95.
39. Bassotti G, Chiarioni G, Vantini I, Morelli A, Whitehead WE. Effect of different doses of erythromycin on colonic motility in patients with slow transit constipation. Z Gastroenterol 1998 36 : 209 13. (Pubitemid 28172483)
40. Park MI, Ferber I, Camilleri M et al. Effect of atilmotin on gastrointestinal transit in healthy subjects: a randomised, placebo-controlled study. Neurogastroenterol Motil 2006 18 : 28 36.
41. Sharma SS, Bhargava N, Mathur SC. Effect of oral erythromycin on colonic transit in patients with idiopathic constipation. A pilot study. Dig Dis Sci 1995 40 : 2446 9.
42. Buhmann S, Kirchhoff C, Wielage C, Mussack T, Reiser MF, Lienemann A. Assessment of large bowel motility by cine magnetic resonance imaging using two different prokinetic agents: a fesibility study. Invest Radiol 2005 40 : 689 94. (Pubitemid 41546834)
43. Longo WE, Vernava AM. Prokinetic agents for lower gastrointestinal motility disorders. Dis Colon Rectum 1993 36 : 696 708. (Pubitemid 23206327)